All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Join our
How to sequence BCMA-directed therapies in early relapsed/ refractory multiple myeloma
At the ESH 7th Translational Research Conference:
Multiple Myeloma
with Martin Kaiser, Mohamad Mohty, and Rakesh Popat
Saturday, October 5, 2024 | 09:10-10:10 CEST
Register nowThis independent educational activity is funded by GSK. All content is developed independently by the faculty. The funders are allowed no influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma hub is an independent medical education platform, sponsored by Sanofi, Bristol Myers Squibb, GSK and Roche, and supported through a grant from Janssen Biotech, Inc. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
On January 19, 2024, the Food and Drug Administration (FDA) authorized a mandate black box warning be included on all chimeric antigen receptor (CAR) T-cell therapies prescribing information, in letters sent to CAR-T therapy manufacturers.
Initially, the benefits of CAR T-cell therapy in lymphoma, leukemia, and multiple myeloma were thought to outweigh the risk of T-cell malignancy. However, in November 2023 the FDA emphasized a need to monitor CAR T-cell therapy clinical trials and post-marketing adverse event reporting throughout patients’ entire lives, enabling the identification of new malignancies and testing for the CAR gene when they occur.
Currently, six CAR T-cell therapies have been approved in the US :
This warning is based on 20 cases of T-cell malignancy reported in 34,000 patients who received approved CAR T-cell therapies. Since then, The International Society for Cell & Gene Therapy published a consensus statement supporting the view CAR T-cell therapies’ benefits to patients outweigh the risks in most cases. However, more information, such as patient characteristics, genetic mutations, and timing of development should be collected to fully elucidate the risk associated with CAR T-cell therapy and T-cell malignancies.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox